Researchers from Carisma Therapeutics Inc. have provided details on the discovery and preclinical evaluation of a novel mesothelin-targeting chimeric antigen receptor macrophage (CAR-M), CT-1119, being developed as a potential solid tumor immunotherapy candidate.
Elevatebio LLC and Affini-T Therapeutics Inc. have entered into a partnership to advance Affini-T's engineered T-cell therapies focused on KRAS, an oncogenic driver mutation in solid tumor cancers.
AZD-4820 was evaluated in a cell viability assay performed in 30 human cancer cell lines, defining 12 different types of cancer, and testing a dose-range of multiplicity of infection (MOI); potent oncolytic activity was observed with EC50 values of <0.1 MOI in nearly all of the tested cells.
Bonum Therapeutics Inc., a spinout of Good Therapeutics Inc., which Roche Holding AG acquired in August, has announced a US$93 million series A financing. Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics. The core platform makes possible the engineering and development of a wide range of medicines.
At the recent Society for Immunotherapy of Cancer meeting, researchers from Dong-A ST Co. Ltd. presented preclinical data for the novel small-molecule general control nonderepressible 2 (GCN2) inhibitor, DA-4507, being developed for the treatment of cancer.
RSS
